PerkinElmer Offering $500M in Senior Notes to Fund Caliper Purchase | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer today announced the pricing of a $500 million offering to be used in part to fund its $600 million purchase of Caliper Life Sciences.

The senior notes carry an aggregate principal amount of 5 percent and are due 2021 at an issue price of 99.372 percent of the principal amount. The issuance of the notes is expected to close Oct. 25. The notes will pay interest on a semi-annual basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.